Chloroquine-containing compounds: a patent review (2010 – 2014)

Bibliography

• Coatney GR. Pitfalls in a discovery: the chronicle of chloroquine. Am J Trop Med Hyg 1963;12:121-8
   PubMed Web of Science ®Google Scholar
• Loeb F, Clark W, Coatney GR, et al. Activity of a new antimalarial agent, chloroquine (SN 7618). J Am Med Assoc 1946;130:1069-70
   PubMed Web of Science ®Google Scholar
• Most H, London IM, Kane CA, et al. Chloroquine for treatment of acute attacks of vivax malaria. J Am Med Assoc 1946;131:963-7
   PubMed Web of Science ®Google Scholar
• Goldberg DE, Slater AF, Cerami A, Henderson GB. Hemoglobin degradation in the malaria parasite Plasmodium falciparum: an ordered process in a unique organelle. Proc Natl Acad Sci USA 1990;87:2931-5
   PubMed Web of Science ®Google Scholar
• Solomon VR, Haq W, Smilkstein M, et al. 4-aminoquinoline derived antimalarials: synthesis, antiplasmodial activity and heme polymerization inhibition studies. Eur J Med Chem 2010;45:4990-6
   PubMed Web of Science ®Google Scholar
• Kumar S, Guha M, Choubey V, et al. Antimalarial drugs inhibiting hemozoin (β-hematin) formation: a mechanistic update. Life Sci 2007;80:813-28
   PubMed Web of Science ®Google Scholar
• Young MD, Moore DV. Chloroquine resistance in Plasmodium falciparum. Am J Trop Med Hyg 1961;10:317-20
   PubMed Web of Science ®Google Scholar
• Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis 2001;184:770-6
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for the treatment of malaria. 2nd edition. 2010. Geneva: World Health Organization, 2010
   Google Scholar
• World Health Organization. WHO model list of essential medicines. 18th edition. 2013. Geneva: World Health Organization, 2013
   Google Scholar
• Freedman A, Steinberg VL. Chloroquine in rheumatoid arthritis; a double blindfold trial of treatment for one year. Ann Rheum Dis 1960;19:243-50
   PubMed Web of Science ®Google Scholar
• Lambert DG. Disease-modifying anti-rheumatic drugs. Anaesth Intensive Care Med 2009;10:35-7
   Google Scholar
• Goldman L, Cole DP, Preston RH. Chloroquine diphosphate in treatment of discoid lupus erythematosus. J Am Med Assoc 1953;152:1428-9
   PubMed Web of Science ®Google Scholar
• Lee S-J, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol 2011;7:718-29
   PubMed Web of Science ®Google Scholar
• Solomon VR, Lee H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol 2009;625:220-33
   PubMed Web of Science ®Google Scholar
• Sasaki K, Tsuno NH, Sunami E, et al. Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer 2010;10:370-80
   PubMed Web of Science ®Google Scholar
• The University of Liverpool. Anti-malarial compounds. US7132431; 2006
   Google Scholar
• Okombo J, Kiara SM, Abdirahman A, et al. Antimalarial activity of isoquine against Kenyan Plasmodium falciparum clinical isolates and association with polymorphisms in Pfcrt and Pfmdr1 genes. J Antimicrob Chemother 2013;68:786-8
   PubMed Web of Science ®Google Scholar
• Portland State University and State of Oregon. Quinoline derivatives and uses thereof. US2013310348; 2013
   Google Scholar
• Peyton DH. Reversed chloroquine molecules as a strategy to overcome resistance in malaria. Curr Top Med Chem 2012;12:400-7
   PubMed Web of Science ®Google Scholar
• Zishiri VK, Joshi MC, Hunter R, et al. Quinoline antimalarials containing a dibemethin group are active against chloroquinone-resistant Plasmodium falciparum and inhibit chloroquine transport via the P. falciparum chloroquine-resistance transporter (Pfcrt). J Med Chem 2011;54:6956-68
   PubMed Web of Science ®Google Scholar
• Gemma S, Campiani G, Butini S, et al. Combining 4-aminoquinoline- and clotrimazole-based pharmacophores toward innovative and potent hybrid antimalarials. J Med Chem 2009;52:502-13
   PubMed Web of Science ®Google Scholar
• Campiani G. Novel 4-amino-quinoline derivatives useful as anti-malaria drugs. US2010093726; 2010
   Google Scholar
• Advanced Applied Physics Solutions Inc. Carbohydrate-metallocene-antimalarial conjugates. WO2010094130; 2010
   Google Scholar
• University of South Florida. Polyacrylate Nanoparticle Drug Delivery. US2010278920; 2010
   Google Scholar
• Georgetown University. Antimalarial Quinolines and Methods of Use Thereof. US2011045100; 2011
   Google Scholar
• Madrid PB, Liou AP, DeRisi JL, Guy RK. Incorporation of an intramolecular hydrogen-bonding motif in the side chain of 4-aminoquinolines enhances activity against drug-resistant P. falciparum. J Med Chem 2006;49:4535-43
   PubMed Web of Science ®Google Scholar
• Stocks PA, Raynes KJ, Bray PG, et al. Novel short chain chloroquine analogues retain activity against chloroquine resistant K1 Plasmodium falciparum. J Med Chem 2002;45:4975-83
   PubMed Web of Science ®Google Scholar
• Nagoya City University. Compound with antimalarial activity and antimalarial drug containing the same as active ingredient. US7973027; 2011
   Google Scholar
• Riscoe MK, Winter RW, Hinrichs DJ. Compounds for treating parasitic disease. US2011251209; 2011
   Google Scholar
• Oregon Health & Science University and The US Department of Veterans Affairs. Compounds, compositions and associated methods comprising 3-aryl quinolines. WO2013106847; 2013
   Google Scholar
• Portland State University and Designmedix Inc. Modified chloroquines with single ring moiety or fused ring moiety. US2011251210; 2011
   Google Scholar
• Designmedix Inc. Modified chloroquines with branched moiety. WO2010065925; 2010
   Google Scholar
• University of Wuerzburg and the University of Heidelberg. Hybrid compounds of 4- and 8-aminoquinolines for the prophylactic and therapeutic treatment of malaria and other parasitic diseases. WO2012048894; 2012
   Google Scholar
• James LM, Wei TKS. Synthesis and use of fluorophore-tagged antimalarials. US2012100555; 2012
   Google Scholar
• Penarete-Vargas DM, Boisson A, Urbach S, et al. A chemical proteomics approach for the search of pharmacological targets of the antimalarial clinical candidate albitiazolium in Plasmodium falciparum using photocrosslinking and click chemistry. PLoS One 2014;9:1-23
   Google Scholar
• Sutherland CJ, Drakeley CJ, Obisike U, et al. The addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in gambian children delays, but does not prevent treatment failure. Am J Trop Med Hyg 2003;69:19-25
   PubMed Web of Science ®Google Scholar
• Gasasira AF, Kamya MR, Achan J, et al. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis 2008;46:985-91
   PubMed Web of Science ®Google Scholar
• Sanofi-Aventis. Association between ferroquine and an artemisinine derivative for treating malaria. US20120258945; 2012
   Google Scholar
• Romanelli F, Smith KM, Hoven AD. Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity. Curr Pharm Des 2004;10:2643-8
   PubMed Web of Science ®Google Scholar
• Vausselin T, Calland N, Belouzard S, et al. The antimalarial ferroquine is an inhibitor of hepatitis C virus. Hepatology 2013;58:86-97
   PubMed Web of Science ®Google Scholar
• Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today’s diseases. Lancet 2003;3:722-7
   PubMed Web of Science ®Google Scholar
• Bönsch C, Kempf C, Mueller I, et al. Chloroquine and its derivatives exacerbate B19V-associated anemia by promoting viral replication. PLoS Negl Trop Dis 2010;4:1-8
   Google Scholar
• Savarino A, Lucia MB, Rastrelli E, et al. Anti-HIV effects of chloroquine. JAIDS J Acquir Immune Defic Syndr 2004;35:223-32
   PubMed Web of Science ®Google Scholar
• Nathoo S, Serghides L, Kain KC. Effect of HIV-1 antiretroviral drugs on cytoadherence and phagocytic clearance of Plasmodium falciparum-parasitised erythrocytes. Lancet 2003;362:1039-41
   PubMed Web of Science ®Google Scholar
• He Z, Qin L, Chen L, et al. Synergy of Human Immunodeficiency Virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo. Antimicrob Agents Chemother 2008;52:2653-6
   PubMed Web of Science ®Google Scholar
• Kinch M, Goldblatt M; Functional Genetics Inc. Methods of inhibiting viral infection. US2012142731; 2012
   Google Scholar
• Obi Justice. Compositions and methods for treating warts associated with viral infections. US2014011838; 2014
   Google Scholar
• Chaozhou Hybribio Ltd. Combined drug for treating verruca diseases. CN104013625; 2014
   Google Scholar
• Genoscience Pharma SAS and Panmed Ltd. Treatment of Hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent. US2013202556; 2013
   Google Scholar
• Halfon P; Panmed Ltd. Treatment of hepatitis C virus. US2014135259; 2014
   Google Scholar
• Roberts PJ, Williams SL, Linch DC. The regulation of neutrophil phospholipase A2 by granulocyte-macrophage colony-stimulating factor and its role in priming superoxide production. Br J Haematol 1996;92:804-14
   PubMed Web of Science ®Google Scholar
• Sakuta H, Yoneda I. Inhibition by SKF525A and quinacrine of endogenous glibenclamide-sensitive K+ channels in follicle-enclosed xenopus oocytes. Eur J Pharmacol 1994;252:117-21
   PubMed Web of Science ®Google Scholar
• Földes-Filep E, Filep JG. Mepacrine inhibits fMLP-induced activation of human neutrophil granulocytes, leukotriene B4 formation, and fMLP binding. J Leukoc Biol 1992;52:545-50
   PubMed Web of Science ®Google Scholar
• Mattsson E, Van Dijk H, Van Kessel K, et al. Intracellular pathways involved in tumor necrosis factor-alpha release by human monocytes on stimulation with lipopolysaccharide or staphylococcal peptidoglycan are partly similar. J Infect Dis 1996;173:212-18
   PubMed Web of Science ®Google Scholar
• Albani Salvatore. Combination therapy method and formulation. US2010021485; 2010
   Google Scholar
• Silva JC, Mariz HA, Rocha LF, et al. Hydroxychloroquine decreases TH17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics (Sao Paulo) 2013;68:766-71
   PubMed Web of Science ®Google Scholar
• Boissy RE. Melanosome transfer to and translocation in the keratinocyte. Exp Dermatol 2003;12(Suppl 2):5–12
   PubMed Web of Science ®Google Scholar
• Ni-Komatsu L, Tong C, Chen G, et al. Identification of quinolines that inhibit melanogenesis by altering tyrosinase family trafficking. Mol Pharmacol 2008;74:1576-86
   Google Scholar
• Hall AM, Orlow SJ. Degradation of tyrosinase induced by phenylthiourea occurs following golgi maturation. Pigment Cell Res 2005;18:122-9
   PubMedGoogle Scholar
• New York University. Methods and agents for treating tyrosinase-positive albinism. WO2014186344; 2014
   Google Scholar
• Gerstein HC, Thorpe KE, Taylor DW, Haynes RB. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas - a randomized trial. Diabetes Res Clin Pract 2002;55:209-19
   PubMed Web of Science ®Google Scholar
• Bevan AP, Christensen JR, Tikerpae J, Smith GD. Chloroquine augments the binding of insulin to its receptor. Biochem J 1995;311:787-95
   PubMed Web of Science ®Google Scholar
• Munro R, Morrison E, McDonald AG, et al. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 1997;56:374-7
   PubMed Web of Science ®Google Scholar
• Wallace DJ. The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus 1996;5(Suppl 1):S59-64
   PubMedGoogle Scholar
• St. Jude Children’s Research Hospital and The Washington University. Use of chloroquine to treat metabolic syndrome. US8440695; 2013
   Google Scholar
• IPCA Laboratories Ltd. Pharmaceutical Combination. US2014128402; 2014
   Google Scholar
• Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006;15:577-83
   PubMed Web of Science ®Google Scholar
• Ashutosh S, Sudhir S. Methods and compositions for managing cardiovascular disease associated with chronic kidney disease. US2013210861; 2013
   Google Scholar
• Bachmeyer C, Benz R, Barth H, et al. Interaction of Clostridium botulinum C2 toxin with lipid bilayer membranes and Vero cells: inhibition of channel function by chloroquine and related compounds in vitro and intoxification in vivo. FASEB J 2001;15:1658-60
   Google Scholar
• Liang YF, Peterson JW, Jackson CA, Reitmeyer JC. Chloroquine inhibition of cholera toxin. FEBS Lett 1990;275:143-5
   PubMed Web of Science ®Google Scholar
• Leppla SH, Dorland RB, Middlebrook JL. Inhibition of diphtheria toxin degradation and cytotoxic action by chloroquine. J Biol Chem 1980;255:2247-50
   PubMed Web of Science ®Google Scholar
• Komiyama T, Swanson JA, Fuller RS. Protection from anthrax toxin-mediated killing of macrophages by the combined effects of furin inhibitors and chloroquine. Antimicrob Agents Chemother 2005;49:3875-82
   PubMed Web of Science ®Google Scholar
• Śolaja BA, Opsenica D, Smith KS, et al. Novel 4-aminoquinolines active against chloroquine-resistant and sensitive P. falciparum strains that also inhibit botulinum serotype A. J Med Chem 2008;51:4388-91
   PubMed Web of Science ®Google Scholar
• Eldredge HB, Denittis A, Duhadaway JB, et al. Concurrent whole brain radiotherapy and short-course chloroquine in patients with brain metastases: a pilot trial. J Radiat Oncol 2013;2:315-21
   Google Scholar
• Choi DS, Blanco E, Kim YS, et al. Chloroquine eliminates cancer stem cells through deregulation of JAK2 and DNMT1. Stem Cells 2014;32:2309-23
   PubMed Web of Science ®Google Scholar
• Kimura T, Takabatake Y, Takahashi A, Isaka Y. Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res 2013;73:3-7
   PubMed Web of Science ®Google Scholar
• University of Pennsylvania. Combination antineoplastic therapy. US2012129810; 2012
   Google Scholar
• Jalan Rajiv. Treatment of liver cancer. US2013315940; 2013
   Google Scholar
• University of Pennsylvania. Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use. WO2012149186; 2012
   Google Scholar
• University of Basel. Combination of lysosomotropic or autophagy modulating agents and a GSK-3 inhibitor for treatment of cancer. WO2013182519; 2013
   Google Scholar
• Medigen Biotechnology Corp and Texas Biogene Inc. Synergistic combination for treating a cancer. WO2013192224; 2013
   Google Scholar
• The Texas A&M University System and Scott & White Healthcare. Diagnosis and treatment of cancer using differentially expressed starvation markers. WO2014018801; 2014
   Google Scholar
• Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital. Hydroxychloroquine linolenate and synthesis method. CN103772277; 2014
   Google Scholar
• Kandula Mahesh. Compositions and methods for the treatment of cancer. WO2014141057; 2014
   Google Scholar
• Oosten V, Bernhard A. Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field. EP2561868; 2013
   Google Scholar
• University of Colorado. Methods and products for treating proliferative diseases. US2011318335; 2011
   Google Scholar
• Guangzhou Kaipu Biological Technology Co. Ltd. Medicament for preventing and treating reproductive organ cancer and application thereof. CN104188969; 2014
   Google Scholar
• Van Gool WA, Weinstein HC, Scheltens PK, Walstra GJM. Effect of hydroxychloroquine on progression of dementia in early alzheimer’s disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 2001;358:455-60
   PubMed Web of Science ®Google Scholar
• D’Amato RJ, Alexander GM, Schwartzman RJ, et al. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity. Nature 1987;327:324-6
   PubMed Web of Science ®Google Scholar
• Corfas G, Murtie JC. Treatments for neuropathy. US2011086878; 2011
   Google Scholar
• Tokugawa K, Yamamoto K, Nishiguchi M, et al. XIB4035, a novel nonpeptidyl small molecule agonist for GFRα-1. Neurochem Int 2003;42:81-6
   PubMed Web of Science ®Google Scholar
• Department of Veterans Affairs and Stanford Junior University. Desethylhydroxychloroquine for the treatment of diseases associated with inflammation. US2014275164; 2014
   Google Scholar
• Guilin Medical University. Application of prednisone and hydroxychloroquine to preparation of compound anti-inflammatory drug. CN103599109; 2014
   Google Scholar
• Mzayek F, Deng H, Mather FJ, et al. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials 2007;2(1):e6
   PubMedGoogle Scholar
• Burrows JN, Chibale K, Wells TNC. The state of the art in anti-malarial drug discovery and development. Curr Top Med Chem 2011;11:1226-54
   PubMed Web of Science ®Google Scholar
• Egan TJ, Hunter R, Kaschula CH, et al. Structure-function relationships in aminoquinolines: effect of amino and chloro groups on quinoline-hematin complex formation, inhibition of beta-hematin formation, and antiplasmodial activity. J Med Chem 2000;43:283-91
   PubMed Web of Science ®Google Scholar
• Nzila A, Ma Z, Chibale K. Drug repositioning in the treatment of malaria and TB. Future Med Chem 2011;3:1413-26
   PubMed Web of Science ®Google Scholar
• Njoroge M, Njuguna NM, Mutai P, et al. Recent approaches to chemical discovery and development against malaria and the neglected tropical diseases human African trypanosomiasis and schistosomiasis. Chem Rev 2014;114:11138-63
   PubMed Web of Science ®Google Scholar
• Van Huijsduijnen RH, Guy RK, Chibale K, et al. Anticancer properties of distinct antimalarial drug classes. PLoS One 2013;8:1-11
   Google Scholar